Virginia Borges, University of Colorado Cancer Center (IMAGE)

University of Colorado Anschutz Medical Campus

Virginia Borges, University of Colorado Cancer Center

Caption

Virginia Borges and colleagues expect phase III trial results to lead to FDA approval of tucatinib against stage IV HER2+ breast cancer

Credit

University of Colorado Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.